Discontinued — last reported Q3 '24
Diagnostics and Genomics — CapEx
Agilent Technologies Diagnostics and Genomics — CapEx remained flat by 0.0% to $74.75M in Q3 2024 compared to the prior quarter. Year-over-year, this metric grew by 45.1%, from $51.50M to $74.75M. Over 2 years (FY 2022 to FY 2024), Diagnostics and Genomics — CapEx shows an upward trend with a 28.5% CAGR.
Analysis
How to read this metric
An increase typically signals planned capacity expansion or modernization, while a decrease may indicate a focus on cash preservation or a completed investment cycle.
Detailed definition
This metric represents the total cash outflows used by the Diagnostics and Genomics segment to acquire, upgrade, and mai...
Peer comparison
Peers in life sciences and diagnostics typically report this as 'Capital Expenditures' or 'Additions to Property, Plant, and Equipment' within segment disclosures.
a_segment_diagnostics_and_genomics_capital_expendituresHistorical Data
| FY'22 | FY'23 | FY'24 | |
|---|---|---|---|
| Value | $181.00M | $206.00M | $299.00M |
| YoY Change | — | +13.8% | +45.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Agilent Technologies's diagnostics and genomics — capex?
- Agilent Technologies (A) reported diagnostics and genomics — capex of $74.75M in Q3 2024.
- How has Agilent Technologies's diagnostics and genomics — capex changed year-over-year?
- Agilent Technologies's diagnostics and genomics — capex increased by 45.1% year-over-year, from $51.50M to $74.75M.
- What is the long-term trend for Agilent Technologies's diagnostics and genomics — capex?
- Over 2 years (2022 to 2024), Agilent Technologies's diagnostics and genomics — capex has grown at a 28.5% compound annual growth rate (CAGR), from $181.00M to $299.00M.
- What does diagnostics and genomics — capex mean?
- The amount of money a business segment spends on physical assets and infrastructure to support its operations.